Invivyd (IVVD) Income from Continuing Operations (2021 - 2025)
Invivyd (IVVD) reported Income from Continuing Operations of 12555000.0 for Q4 2025, up 34.71% on a YoY basis from 9320159.63 in Q4 2024, and down 13.9% quarter-over-quarter from 11023000.0 in Q3 2025.
Invivyd (IVVD) Income from Continuing Operations (2021 - 2025) Analysis & Trends
Invivyd has reported Income from Continuing Operations for 5 years, with the latest figure at 12555000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations rose 34.71% year-over-year to 12555000.0; the trailing twelve-month figure through Dec 2025 stood at 55560000.0 (up 68.59% YoY), and the FY2025 full-year result was 55560000.0, up 68.59% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 12555000.0, down from 11023000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 11023000.0 in Q3 2025, with the low at 100739000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 46003100.0 across 5 years, with a median of 46710000.0 in 2022.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 160.25% — and 2025, when it soared 82.31%.
- Invivyd's Income from Continuing Operations stood at 83090000.0 in 2021, then soared by 41.98% to 48212000.0 in 2022, then tumbled by 59.2% to 76752000.0 in 2023, then soared by 74.95% to 19229000.0 in 2024, then soared by 34.71% to 12555000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 12555000.0 (Q4 2025), 11023000.0 (Q3 2025), and 15060000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Invivyd | 168.41 Mn | -58.28 Mn | - | -12.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12.56 Mn |
| Sep 30, 2025 | -11.02 Mn |
| Jun 30, 2025 | -15.06 Mn |
| Mar 31, 2025 | -16.92 Mn |
| Dec 31, 2024 | -19.23 Mn |
| Sep 30, 2024 | -62.31 Mn |
| Jun 30, 2024 | -49.25 Mn |
| Mar 31, 2024 | -46.09 Mn |
| Dec 31, 2023 | -76.75 Mn |
| Sep 30, 2023 | -43.06 Mn |
| Jun 30, 2023 | -53.88 Mn |
| Mar 31, 2023 | -39.07 Mn |
| Dec 31, 2022 | -48.21 Mn |
| Sep 30, 2022 | -47.33 Mn |
| Jun 30, 2022 | -51.75 Mn |
| Mar 31, 2022 | -100.74 Mn |
| Dec 31, 2021 | -83.09 Mn |
| Sep 30, 2021 | -60.37 Mn |
| Jun 30, 2021 | -44.67 Mn |
| Mar 31, 2021 | -38.71 Mn |